CN108026170B - 抗cd71抗体、可活化抗cd71抗体及其使用方法 - Google Patents

抗cd71抗体、可活化抗cd71抗体及其使用方法 Download PDF

Info

Publication number
CN108026170B
CN108026170B CN201680038952.XA CN201680038952A CN108026170B CN 108026170 B CN108026170 B CN 108026170B CN 201680038952 A CN201680038952 A CN 201680038952A CN 108026170 B CN108026170 B CN 108026170B
Authority
CN
China
Prior art keywords
antibody
seq
conjugated
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680038952.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN108026170A (zh
Inventor
J.G.萨格特
K.A.蒂普顿
J.A.特雷特
S.辛格
A.Y.威维
L.R.德斯诺耶斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytomx Therapeutics Inc
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Priority to CN202210118691.XA priority Critical patent/CN114507283A/zh
Publication of CN108026170A publication Critical patent/CN108026170A/zh
Application granted granted Critical
Publication of CN108026170B publication Critical patent/CN108026170B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680038952.XA 2015-05-04 2016-05-04 抗cd71抗体、可活化抗cd71抗体及其使用方法 Active CN108026170B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210118691.XA CN114507283A (zh) 2015-05-04 2016-05-04 抗cd71抗体、可活化抗cd71抗体及其使用方法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201562156838P 2015-05-04 2015-05-04
US62/156838 2015-05-04
US201562257321P 2015-11-19 2015-11-19
US201562257484P 2015-11-19 2015-11-19
US62/257321 2015-11-19
US62/257484 2015-11-19
US201662277775P 2016-01-12 2016-01-12
US62/277775 2016-01-12
US201662310553P 2016-03-18 2016-03-18
US62/310553 2016-03-18
US201662315276P 2016-03-30 2016-03-30
US62/315276 2016-03-30
PCT/US2016/030738 WO2016179257A2 (en) 2015-05-04 2016-05-04 Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210118691.XA Division CN114507283A (zh) 2015-05-04 2016-05-04 抗cd71抗体、可活化抗cd71抗体及其使用方法

Publications (2)

Publication Number Publication Date
CN108026170A CN108026170A (zh) 2018-05-11
CN108026170B true CN108026170B (zh) 2022-03-01

Family

ID=55967461

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680038952.XA Active CN108026170B (zh) 2015-05-04 2016-05-04 抗cd71抗体、可活化抗cd71抗体及其使用方法
CN202210118691.XA Pending CN114507283A (zh) 2015-05-04 2016-05-04 抗cd71抗体、可活化抗cd71抗体及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210118691.XA Pending CN114507283A (zh) 2015-05-04 2016-05-04 抗cd71抗体、可活化抗cd71抗体及其使用方法

Country Status (26)

Country Link
US (3) US10179817B2 (enExample)
EP (2) EP4029880A1 (enExample)
JP (3) JP2018520991A (enExample)
KR (1) KR20180011127A (enExample)
CN (2) CN108026170B (enExample)
AU (2) AU2016258628B2 (enExample)
BR (1) BR112017023862A2 (enExample)
CA (2) CA2984945A1 (enExample)
CY (1) CY1125011T1 (enExample)
DK (1) DK3292149T3 (enExample)
EA (1) EA201792413A1 (enExample)
ES (1) ES2910407T3 (enExample)
HR (1) HRP20220172T1 (enExample)
HU (1) HUE057720T2 (enExample)
IL (2) IL255416B2 (enExample)
LT (1) LT3292149T (enExample)
MX (2) MX2017014139A (enExample)
MY (2) MY194184A (enExample)
PL (1) PL3292149T3 (enExample)
PT (1) PT3292149T (enExample)
RS (1) RS62956B1 (enExample)
SG (1) SG10201913762QA (enExample)
SI (1) SI3292149T1 (enExample)
TW (2) TWI726879B (enExample)
WO (1) WO2016179257A2 (enExample)
ZA (1) ZA201707645B (enExample)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033734A1 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand
BR112016001611B1 (pt) * 2013-07-25 2024-01-09 Cytomx Therapeutics, Inc Anticorpo ativável multiespecífico, uso terapêutico do mesmo, molécula de ácido nucleico isolada, vetor e método para produzir um anticorpo ativável multiespecífico
US20150087810A1 (en) 2013-09-25 2015-03-26 Cytomx Therapeutics, Inc. Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
EP3628328B1 (en) * 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
MY194184A (en) * 2015-05-04 2022-11-17 Cytomx Therapeutics Inc Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
US10765742B2 (en) 2015-07-17 2020-09-08 The Trustees Of Columbia University In The City Of New York Methods of treating CD166-expressing cancer
MX2018016253A (es) 2016-07-05 2019-09-09 Biomarin Tech Bv Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos.
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
TW202323287A (zh) 2016-11-28 2023-06-16 日商中外製藥股份有限公司 包含抗原結合域與運送部分的多胜肽
KR20230073346A (ko) 2016-11-28 2023-05-25 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
EP3551667A4 (en) 2016-12-09 2020-06-17 Seattle Genetics, Inc. Bivalent antibodies masked by coiled coils
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
RU2759952C2 (ru) 2016-12-14 2021-11-19 Янссен Байотек, Инк. Cd8a-связывающие домены типа iii фибронектина
FR3062213B1 (fr) * 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
EP3635009A1 (en) 2017-06-07 2020-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
KR20200040819A (ko) 2017-08-16 2020-04-20 브리스톨-마이어스 스큅 컴퍼니 항체를 표적화하기 위한 항 ctla-4 프로바디 치료제
CN111278467B (zh) * 2017-10-14 2024-07-30 艾伯维公司 抗cd71可活化抗体药物缀合物和其使用方法
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
WO2019107380A1 (ja) 2017-11-28 2019-06-06 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
MX2020005160A (es) 2017-11-28 2020-08-20 Chugai Pharmaceutical Co Ltd Molecula de union a ligando que tiene actividad de union a ligando ajustable.
KR102178946B1 (ko) 2018-01-30 2020-11-13 주식회사 엘지화학 직병렬 변환 장치 및 이를 구비한 배터리 모듈
IL322464A (en) 2018-02-07 2025-09-01 Regeneron Pharma Methods and compositions for administering therapeutic protein
EP3769309A1 (en) 2018-03-20 2021-01-27 Cytomx Therapeutics Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
BR112020018948A2 (pt) * 2018-03-23 2021-01-05 Seattle Genetics, Inc. Uso de conjugados de fármaco e anticorpo que compreendem agentes de interrupção de tubulina para tratar tumor sólido
JP7460609B2 (ja) 2018-05-14 2024-04-02 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン－２ポリペプチド及びその使用方法
SG11202011308VA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable cytokine polypeptides and methods of use thereof
CN108663521A (zh) * 2018-05-17 2018-10-16 北京迈迪金生物科技股份有限公司 一种量子点免疫层析法膀胱癌检测试剂盒
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
CN108614112A (zh) * 2018-05-25 2018-10-02 北京迈迪金生物科技股份有限公司 一种胶体金法半定量检测人转铁蛋白受体cd71检测试剂盒
WO2019230868A1 (ja) 2018-05-30 2019-12-05 中外製薬株式会社 単ドメイン抗体含有リガンド結合分子
KR20210081324A (ko) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
SG11202100934PA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) * 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CN112521504B (zh) * 2018-09-27 2022-08-16 暨南大学 一种抗人egfr的纳米抗体及其应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3883964A1 (en) * 2018-11-20 2021-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
WO2020104479A1 (en) * 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
US12049505B2 (en) 2018-12-06 2024-07-30 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
JP7538798B2 (ja) * 2018-12-21 2024-08-22 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム リン酸化ダイサー抗体およびその使用方法
WO2020127885A1 (en) * 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
BR112021023735A2 (pt) 2019-06-05 2022-01-04 Chugai Pharmaceutical Co Ltd Molécula de ligação de sítio de clivagem de anti-corpo
US20220251206A1 (en) 2019-06-11 2022-08-11 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
US11628222B2 (en) 2019-10-14 2023-04-18 Aro Biotherapeutics Company CD71 binding fibronectin type III domains
US20210147566A1 (en) * 2019-10-18 2021-05-20 Distributed Bio, Inc. Antibodies and uses thereof
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
WO2021130313A1 (en) 2019-12-23 2021-07-01 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for nucleotide deamination in the treatment of stargardt disease
IL297148A (en) * 2020-04-08 2022-12-01 Janssen Biotech Inc Compositions and methods for blood-brain barrier delivery
AU2021254279A1 (en) 2020-04-09 2022-11-10 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
CN115956089A (zh) 2020-05-04 2023-04-11 加利福尼亚大学董事会 抑制性抗enpp1抗体
KR20230043116A (ko) * 2020-06-24 2023-03-30 사프렘 테크놀로지스 비.브이. 단일 도메인 항체, 사포닌 및 이펙터 분자의 접합체, 이를 포함하는 약학적 조성물, 상기 약학적 조성물의 치료 용도
US11512113B2 (en) 2020-08-11 2022-11-29 Janux Therapeutics, Inc. Cleavable linker compositions and methods
CN116761635A (zh) 2020-11-24 2023-09-15 诺华股份有限公司 Bcl-xl抑制剂抗体药物缀合物及其使用方法
WO2022125576A1 (en) 2020-12-09 2022-06-16 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
MX2023007901A (es) 2020-12-31 2023-07-11 Sanofi Sa Acopladores de celulas asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123.
CA3215367A1 (en) 2021-04-14 2022-10-20 Swapnil Kulkarni Fn3 domain-sirna conjugates and uses thereof
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
AU2022309028A1 (en) 2021-07-09 2024-01-25 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
CA3226001A1 (en) 2021-07-16 2023-01-19 Anton Jan Van Zonneveld Oligonucleotide for inhibiting quaking activity
CN117794953A (zh) * 2021-08-03 2024-03-29 豪夫迈·罗氏有限公司 双特异性抗体及使用方法
CR20240139A (es) * 2021-09-01 2024-06-14 Biogen Ma Inc Anticuerpos del receptor antitransferrina y usos de los mismos
KR20240118749A (ko) 2021-10-15 2024-08-05 싸이톰스 테라퓨틱스, 인크. 활성화 가능한 폴리펩타이드 복합체
EP4479535A1 (en) 2022-02-14 2024-12-25 ProQR Therapeutics II B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
EP4496816A1 (en) 2022-03-23 2025-01-29 CytomX Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
CN119301151A (zh) 2022-03-25 2025-01-10 西托姆克斯治疗公司 可激活双锚定掩蔽分子和其使用方法
US20250215110A1 (en) 2022-04-01 2025-07-03 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
US20250230239A1 (en) 2022-04-01 2025-07-17 Cytomx Therapeutics, Inc. Cd3-binding proteins and methods of use thereof
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
EP4519437A2 (en) 2022-05-06 2025-03-12 Academisch Ziekenhuis Leiden (h.o.d.n. LUMC) Oligonucleotide
JP2025517332A (ja) 2022-05-20 2025-06-05 ノバルティス アーゲー 抗体薬物コンジュゲート
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
AU2023274452A1 (en) 2022-05-27 2025-01-16 Innate Pharma Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
KR20250054842A (ko) * 2022-07-29 2025-04-23 리제너론 파마슈티칼스 인코포레이티드 뇌 및 근육으로의 트랜스페린 수용체(tfr)-매개 전달을 위한 조성물 및 방법
EP4565690A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
WO2024030858A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
AR130077A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Substratos escindibles por proteasas, y métodos de uso de los mismos
WO2024030845A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
TW202424184A (zh) 2022-08-01 2024-06-16 美商Ｃｙｔｏｍｘ生物製藥公司 蛋白酶可切割部分及其使用方法
WO2024097851A1 (en) * 2022-11-02 2024-05-10 Vanderbilt University Cd71-blocking antibodies for treating autoimmune and inflammatory diseases
WO2024216194A1 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
CN120936384A (zh) 2023-04-12 2025-11-11 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
WO2025024334A1 (en) 2023-07-21 2025-01-30 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025133132A1 (en) * 2023-12-20 2025-06-26 Institut National De La Sante Et De La Recherche Medicale Novel anti-tfr1 (cd71) antibodies for cancer treatment
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2749339A1 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2011073943A1 (fr) * 2009-12-16 2011-06-23 Centre National De La Recherche Scientifique (Cnrs) Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
WO2014189973A2 (en) * 2013-05-20 2014-11-27 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
CN104540518A (zh) * 2012-04-27 2015-04-22 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
CN104661677A (zh) * 2012-06-22 2015-05-27 西托姆克斯治疗公司 抗Jagged 1/Jagged 2交叉反应抗体、可活化的抗Jagged抗体及其使用方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4364934A (en) 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
US4624925A (en) 1979-12-04 1986-11-25 Ortho Pharmaceutical Corporation Hybrid cell line for producing monoclonal antibody to a human early thymocyte antigens, antibody, and methods
US4691010A (en) 1979-12-04 1987-09-01 Ortho Pharmaceutical Corporation Hybrid cell line for producing monoclonal antibody to a human early thymocyte antigen, antibody, and methods
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
WO1988001513A1 (fr) 1986-08-28 1988-03-10 Teijin Limited Complexe d'anticorps cytocide et procede de production
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5648469A (en) 1992-04-20 1997-07-15 The Salk Institute For Biological Studies Monoclonal antibodies reactive with transferrin receptor cytoplasmic domain
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
ES2368387T5 (es) 2000-10-09 2019-03-07 Cytomx Therapeutics Inc Anticuerpos terapéuticos y que inducen tolerancia
US20050255464A1 (en) * 2001-07-19 2005-11-17 Hagen Frederick S Methods for the identification of peptidyl compounds interacting with extracellular target molecules
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
US7976841B2 (en) 2004-04-30 2011-07-12 Institut National De La Sante Et De La Recherche Anti TfR antibody
WO2005121179A2 (en) 2004-06-07 2005-12-22 Raven Biotechnologies, Inc. Transferrin receptor antibodies
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
EP1919931A4 (en) 2005-08-31 2010-01-20 Univ California CELLULAR PEPTIDE SEQUENCE LIBRARIES (CLIPS) AND METHOD OF USE THEREOF
JP2009529522A (ja) 2006-03-10 2009-08-20 ディアト 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤
CN101245107B (zh) 2007-02-14 2010-10-13 中国人民解放军军事医学科学院生物工程研究所 抗人转铁蛋白受体人源抗体及其应用
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
WO2011130164A2 (en) 2010-04-13 2011-10-20 The Regents Of The University Of California Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
FR2959416B1 (fr) 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
BR112013013083A2 (pt) 2010-11-30 2016-12-13 Genentech Inc métodos para transportar um composto, para aumentar exposição do cns a um composto, para diminuir a depuração de um composto, para aumentar a retenção no cns de um composto, para otimizar a farmacocinética, para tratar um distúrbio neurológico em um mamífero, para desenvolver um anticorpo, anticorpo, fragmento de anticorpo, anticorpo multiespecífico e uso de um anticorpo
BR112013026423A2 (pt) 2011-04-20 2016-11-29 Roche Glycart Ag método e construtos para a passagem de pendente do ph da barreira sangue-cérebro
EP2708560A4 (en) 2011-05-09 2015-01-14 Perseus Proteomics Inc ANTIBODIES FOR THE SPECIFIC DETECTION OF TRANSFERRIN RECEPTORS
TWI450727B (zh) 2011-12-29 2014-09-01 Ind Tech Res Inst 抗人類輸鐵蛋白受體的單域抗體與其應用
AU2013203422A1 (en) * 2012-01-06 2013-07-18 Bioalliance C.V. Anti-transferrin receptor antibodies and methods using same
KR102031317B1 (ko) 2012-05-21 2019-10-14 제넨테크, 인크. 혈액-뇌 장벽 수송의 안전성을 개선하는 방법
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
US20150197574A1 (en) 2012-08-02 2015-07-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of transferrin receptor antagonist for the treatment of thalassemia
EP2882844B1 (en) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
KR20150039798A (ko) 2012-08-29 2015-04-13 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀
DK2918603T3 (en) 2012-11-08 2018-10-15 Univ Miyazaki ANTIBODY STANDING TO SPECIFICALLY RECOGNIZE TRANSFERRIN RECEPTOR
WO2014088942A1 (en) 2012-12-03 2014-06-12 The Johns Hopkins University Diagnostic biomarkers and therapeutic targets for pancreatic cancer
BR112015012014A2 (pt) 2012-12-04 2017-07-11 Abbvie Inc proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
WO2014152199A1 (en) 2013-03-15 2014-09-25 Abbvie Inc. Antibody drug conjugate (adc) purification
WO2014144060A1 (en) 2013-03-15 2014-09-18 Alper Biotech, Llc Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof
US10906981B2 (en) 2013-07-19 2021-02-02 The Regents Of The University Of California Compositions and methods related to structures that cross the blood brain barrier
BR112016001611B1 (pt) * 2013-07-25 2024-01-09 Cytomx Therapeutics, Inc Anticorpo ativável multiespecífico, uso terapêutico do mesmo, molécula de ácido nucleico isolada, vetor e método para produzir um anticorpo ativável multiespecífico
US9994641B2 (en) 2013-12-25 2018-06-12 Jcr Pharmaceuticals Co., Ltd. Anti-human transferrin receptor antibody that passes through blood-brain barrier
BR112016015589A2 (pt) 2014-01-06 2017-10-31 Hoffmann La Roche módulos de trânsito monovalentes para a barreira hematoencefálica
MX373458B (es) 2014-01-10 2020-05-11 Byondis Bv Metodo para purificar conjugados de anticuerpo-farmaco enlazados a cisteina.
JP2017511376A (ja) 2014-03-21 2017-04-20 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート
MY194184A (en) * 2015-05-04 2022-11-17 Cytomx Therapeutics Inc Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
UA123053C2 (uk) 2015-06-24 2021-02-10 Ф. Хоффманн-Ля Рош Аг Антитіло до рецептора трансферину зі спеціально підібраною афінністю
MX2018000569A (es) 2015-07-22 2018-09-27 Inatherys Anticuerpos anti-tfr y su uso en el tratamiento de trastornos proliferativos e inflamatorios.
CN111278467B (zh) 2017-10-14 2024-07-30 艾伯维公司 抗cd71可活化抗体药物缀合物和其使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2749339A1 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2011073943A1 (fr) * 2009-12-16 2011-06-23 Centre National De La Recherche Scientifique (Cnrs) Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
CN104540518A (zh) * 2012-04-27 2015-04-22 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
CN104661677A (zh) * 2012-06-22 2015-05-27 西托姆克斯治疗公司 抗Jagged 1/Jagged 2交叉反应抗体、可活化的抗Jagged抗体及其使用方法
WO2014189973A2 (en) * 2013-05-20 2014-11-27 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use

Also Published As

Publication number Publication date
ZA201707645B (en) 2023-10-25
IL310251A (en) 2024-03-01
WO2016179257A2 (en) 2016-11-10
LT3292149T (lt) 2022-03-10
TWI726879B (zh) 2021-05-11
AU2021257886A1 (en) 2021-11-18
CA3176004A1 (en) 2016-11-10
AU2016258628B2 (en) 2021-11-11
EP3292149A2 (en) 2018-03-14
BR112017023862A2 (pt) 2018-07-17
HUE057720T2 (hu) 2022-06-28
JP2022120070A (ja) 2022-08-17
EP4029880A1 (en) 2022-07-20
RS62956B1 (sr) 2022-03-31
PL3292149T3 (pl) 2022-03-21
US10179817B2 (en) 2019-01-15
IL255416B2 (en) 2024-06-01
TW202146456A (zh) 2021-12-16
US11267896B2 (en) 2022-03-08
MX2017014139A (es) 2018-07-06
IL255416B1 (en) 2024-02-01
SI3292149T1 (sl) 2022-04-29
SG10201913762QA (en) 2020-03-30
CA2984945A1 (en) 2016-11-10
TWI787796B (zh) 2022-12-21
TW201704265A (zh) 2017-02-01
PT3292149T (pt) 2022-04-04
KR20180011127A (ko) 2018-01-31
US20160355599A1 (en) 2016-12-08
US20190202927A1 (en) 2019-07-04
AU2016258628A1 (en) 2017-11-30
HRP20220172T1 (hr) 2022-06-24
EA201792413A1 (ru) 2018-06-29
EP3292149B1 (en) 2021-12-01
ES2910407T3 (es) 2022-05-12
CN114507283A (zh) 2022-05-17
HK1250035A1 (en) 2018-11-23
CY1125011T1 (el) 2023-01-05
CN108026170A (zh) 2018-05-11
MX2023001234A (es) 2023-03-03
MY199496A (en) 2023-11-01
DK3292149T3 (da) 2022-02-28
JP2024147648A (ja) 2024-10-16
MY194184A (en) 2022-11-17
US20220306759A1 (en) 2022-09-29
IL255416A0 (en) 2017-12-31
JP2018520991A (ja) 2018-08-02
WO2016179257A3 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
CN108026170B (zh) 抗cd71抗体、可活化抗cd71抗体及其使用方法
JP7165217B2 (ja) 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
CN107849133B (zh) 抗cd166抗体、可活化抗cd166抗体及其使用方法
CN108368170B (zh) 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
CN114685611B (zh) 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
CN110662766A (zh) Cd147抗体、可激活cd147抗体及其制备和使用方法
WO2016179335A1 (en) Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
EP3762420A1 (en) Activatable cd147 antibodies and methods of making and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant